DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari Et Al USOO8480637B2 (12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent: Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902,904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al. .................... 216,56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al. ... ... 424/422 Sharath Hosali, Austin, TX (US); Ryan 379.83- w A SE us et al. .... ... 210,490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4, 1999 Keller et al. ... 510,483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al. ........................ 210,490 5,948.255. A * 9/1999 Keller et al. ... 210,321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 1 1/1999 Chu et al. ........................ 516,41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al. ...................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this W W 38E. d38 past list: listed under 35 W. Wooyo 12/2009 M YW- y to 12 dayaWS. OTHER PUBLICATIONS (21) Appl. No.: 12/618,233 “Under the Counter: The Diversion and Abuse of Controlled Pre 1-1. scription Drugs in the US.” The National Center on Addiction and (22) Filed: Nov. 13, 2009 Substance Abuse (CASA) at Columbia University, New York, NY. (65) Prior Publication Data CASA, Jul. 2005. US 2010/0152699 A1 Jun. 17, 2010 (Continued) Primary Examiner — Manuel Mendez Related U.S. Application Data Assistant Examiner — Gerald Landry, II (60) Provisional application No. 61/114,687, filed on Nov. (74) Attorney, Agent, or Firm — Parker Highlander PLLC 14, 2008, provisional application No. 61/168,844, (57) ABSTRACT filed on Apr. 13, 2009. A nanochannel delivery device and method of manufacturing (51) Int. Cl and use. The nanochannel delivery device comprises an inlet, A. iM 25/00 (2006.01) an outlet, and a nanochannel. The nanochannel may be ori (52) U.S. Cl ented parallel to the primary plane of the nanochannel deliv USPG 604/264: 604/43 ery device. The inlet and outlet may be in direct fluid com (58) Field of- -Classification - - - - - - - - - - - - - - - - - - - - - - - Search- - - - - - - - - - - - - - - - - - - - s U1Ca1OW1icati ith th aOClaeh 1. CPC ....................................................... B82Y 4O/OO 15 Claims, 35 Drawing Sheets US 8,480,637 B2 Page 2 U.S. PATENT DOCUMENTS Nath et al., “Buprenorphine pharmacokinetics: relative bioavail 6,044,981 4, 2000 Chu et al. ...................... 210,490 ability of Sublingual tablet and liquid formulations.” J. Clin. 7,025,871 4, 2006 Broadley et al. 205,793 Pharmacol. 39:619-623, 1999. 7,135,144 11, 2006 Christel et al. ..... 422,527 Report Stakeholder Workshop on a National Buprenorphine Program 7,326,561 2, 2008 Goodman et al. 435/286.5 Health Canada Nov. 18, 2004. 2004.0011647 1, 2004 Broadley et al. ... ... 204,435 Samhsa, "Overview of Findings from the 2002 National Survey on 2004/O116905 6, 2004 Pedersen et al. 604/890.1 Drug Use and Health.” Rockville, MD, DHHS publication, SMA 2004/0260418 12, 2004 Staats ......... 7OO/97 O3-3774. 2006, O180469 8, 2006 Han et al. .... ... 204f601 Samhsa, “Results from the 2003 National Survey on Drug Use and 2007/0066138 3, 2007 Ferrari et al. ... 439,607.01 Health: National Findings.” Rockeville, MD, DHHS publication, 2007/OO77273 4, 2007 Martin et al. ... 424/423 S.MA 04-3964. 2008.OO73506 3, 2008 Lazar ............. 250/288 Samhsa, “The DAWN Report: Oxycodaone, hydrocodone, and 2009/0214392 8, 2009 Kameoka et al. ............. 422/102 polydrug use.” 2002. Jul. 2004 http://oas. Samhsa.gov/2k4/ oxycodone?oxycodone.cfm. OTHER PUBLICATIONS Extended European Search Report issued in European Application No. 09826831, mailed Jul. 12, 2012. “The Economic Costs of Drug Abuse in the United States,” www whitehousedrugpolicy.gov, Sep. 2001. * cited by examiner U.S. Patent Jul. 9, 2013 Sheet 1 of 35 US 8,480,637 B2 U.S. Patent Jul. 9, 2013 Sheet 3 Of 35 US 8,480,637 B2 FIG. 20 FIG. 2D U.S. Patent Jul. 9, 2013 Sheet 5 Of 35 US 8,480,637 B2 Ø FIG. 3B // .//…***~~~~).... U.S. Patent Jul. 9, 2013 Sheet 6 of 35 US 8,480,637 B2 FIG. 3D U.S. Patent Jul. 9, 2013 Sheet 7 Of 35 US 8,480,637 B2 FIG. 3E S /// (/. FIG. 3F U.S. Patent Jul. 9, 2013 Sheet 8 Of 35 US 8,480,637 B2 FIG. 3G U.S. Patent Jul. 9, 2013 Sheet 9 Of 35 US 8,480,637 B2 U.S. Patent Jul. 9, 2013 Sheet 10 Of 35 US 8,480,637 B2 N N SN • ---x^^ 3- ------- ------- --/-)-2-// 2 ii if 11161, 1% ^ % 1, -----: 1444 u-220 2.3 3. 3--------- a. --- 2. 2. - If I i 3333222222222222222232 -: --. 1. 2. 33.a--- - 3 3.^x. 2. 262. % 32 23,22. 3 2--- 32. 23 s%3. -3 3 2 3 32. 3.33 2. 22- 2. 32 3 2. - × - × 32 23 23. 3 3 333 3 2. 332. 3 2. 222222222222223. 2 33.33 3.a. 2 22. --------------- --- M 32222222 3- ---. ----- . - 2 3 W. 23 3 36. 2 23-dz2. 2 T 3.3223.3 22 2. 3. % 2. 3 --> 33X a. - 3.>32 a. 32.--- 222 %32.- - ^^^- 3^ 2,it initial33 3 3 - 250 23233 22 33 22 3 3 2 2. 3 322. × 33223222222222 2. --> 2. 3 3, 33. - 2 33.3 23 U.S. Patent Jul. 9, 2013 Sheet 13 Of 35 US 8,480,637 B2 FIG. 5H U.S. Patent Jul. 9, 2013 Sheet 14 of 35 US 8,480,637 B2 U.S. Patent Jul. 9, 2013 Sheet 15 Of 35 US 8,480,637 B2 430 3 - 420 3 3 2 3 3 & s3 %3 2. 33 TITIATIII, III, III ITT.III. T.I.T.3 - 450 Z 32. 3 3 3 410 3 - - - - - 2 3 2 323 32. 3 FIG. 8A U.S. Patent Jul. 9, 2013 Sheet 16 of 35 US 8,480,637 B2 SS é2. & SSSSSSSSSSSSSS SSS3 3Se 22. : s illili 3- -. - - 2. ^^^X. XX ^ --- 23 3. 2 3- ---XX.22.2,2. 3.2. 2 3-2. d 32 23 3 3.------- 2. ----- - -> 2.3 3s 3in x. 2. 2. xxx^ 3. ^s 22 2. 2 2. &-- a MX^ 2 2.3 3 2. 2. %s 32, 3 32 2 3 3 22 % 3 3.3 ^.3. &2. 2,222. 3 2 3 33. 33 3. 2. 2.32 3/410 3 ------------ 2. W. 2.2.3 2,2. 33 -----> 3 X 3% 2 3 22:32:3- - 3s322 2. a. × 22. 32. 3 2 > 3 --- 2 % % 3 3% 3 3 - 2.3 32. FIG. 8B SNS <sS S S SxYSSYS SSSSSSS NN M - X ^^^^ 223 2.%3 3 M 3 %23. 2 ::::::: ---------> Ll l ill Hill ill &: Lil --- x. ^ -- ^. t 2 2.. 32 333 3 2 .. 22. ^^^X^^. -- 232 ..a - ---- 8. ^^^ ^ M 22. 2. 2. 333.22.22%. 3. 32, 3 - ---. - 3-. - M - 6 - M - 3 %^. 3 2. 22 32 3 3 233 3 3. % 3 2 32 32 3 -. 23 3% 32222222223 23 U.S. Patent Jul. 9, 2013 Sheet 17 Of 35 US 8,480,637 B2 41 1-1 441 441 421 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS SSSSSS NXXX SSS SS Sy y SS SS NY. S. SSS SS SS SS y^N SS NX SS SSSSSS Ny S SS SNSS - N- - SS Š SSX N NN N N N 411 N NSy NS. S SSSSSSSSSN S S SS S S NSSSSSSSSSSSSSSSSSSSSS N N NN N N r SSN SSN NSSSSS SS SSSN S&S SSSSSSSSN NSNSX-N SS S \ N N& S. SSSSSN N SX N S S N N N ySN N SSN NNS w N SS. NNN. ŠSSS N N SSSSSSSSSSSSSSSSS y - s s S. S. S. N NS. S N N S SS S NS S S SS N S N SN NNSS SSNS N&YYXX^XXX S. SSSS N NxYxxx N - TTT T S ------------- ------ 3 3 %3^ & 3 8 j i ; É.i.i. i. lili 323-y 3. & 450 2 232. 333 %32 2% ---. a------> - s 3. % 3 % 2. M 2 & ^^ M 2. 3 2. 3 33 - --- 3.32. 2.222222.6% % 3 32 W. 3 2. 2 2. 3 2. 2. 3 33 23 3 % 3 2. 3. 3 s22. 3% U.S. Patent Jul. 9, 2013 Sheet 18 Of 35 US 8,480,637 B2 421 441 430 3 L 2. 420 22--> : . - - -3. - - 1--------1-------1------------->3 & 3 32222222 3. --- 33-4402. % 2. 2 222222222222.222222,3 3. 3. a 3 450 21. a %--- ---> 3 - 3.3 3--- 22222222222 3 3.a.3 2. 2 2 22.22, 3322 3.3 2. 23 %2. ----------------- 3 -1- 3 22 3 32 3. 32 % 3 2.----> 33 FIG. 8F 421 441 430 420 3 440 2% 32 y 3 450 2 3.3. 3 --- 233 - 22. 3 %23. 22323 2. 3 6 3 3 3 3 3 3N410a- 2.-------> 2.:------- 2222222222, 2 -a- W 3 3. 2. 2. 22 3. 3. 2. -3 2322222222 3 322222222222 3.- - 3 - U.S. Patent Jul. 9, 2013 Sheet 19 Of 35 US 8,480,637 B2 445 N T nitri I E. FIG. 8H 450 410 FIG. 8 U.S. Patent Jul. 9, 2013 Sheet 21 Of 35 US 8,480,637 B2 550 FIG.
Load more

Recommended publications
  • Ep 2492268 A1
    (19) & (11) EP 2 492 268 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.08.2012 Bulletin 2012/35 C07D 407/10 (2006.01) A61K 31/405 (2006.01) (21) Application number: 12168896.4 (22) Date of filing: 20.07.2007 (84) Designated Contracting States: • Wynne, Graham Michael AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Abingdon, Oxfordshire OX14 4RY (GB) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Dorgan, Colin Richard SI SK TR Abingdon, Oxfordshire OX14 4RY (GB) Designated Extension States: • Johnson, Peter David AL BA HR MK RS Abingdon, oxfordshire OX14 4RY (GB) (30) Priority: 22.07.2006 GB 0614608 (74) Representative: Hollywood, Jane Constance 04.12.2006 GB 0624176 Kilburn & Strode LLP 20 Red Lion Street (62) Document number(s) of the earlier application(s) in London WC1R 4PJ (GB) accordance with Art. 76 EPC: 07766323.5 / 2 046 740 Remarks: This application was filed on 22-04-2012 as a (71) Applicant: Oxagen Limited divisional application to the application mentioned Oxfordshire OX14 4RY (GB) under INID code 62. (72) Inventors: • Armer, Richard Edward Abingdon, Oxfordshire OX14 4RY (GB) (54) Compounds having CRTH2 antagonist activity (57) Compounds of general formula (1) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically ac- ceptable salts, hydrates, solvates, complexes or prod- rugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, aller- gic rhinitis and atopic dermatitis. EP 2 492 268 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 492 268 A1 Description [0001] The present invention relates to compounds which are useful as pharmaceuticals, to methods for preparing these compounds, compositions containing them and their use in the treatment and prevention of allergic diseases such 5 as asthma, allergic rhinitis and atopic dermatitis and other inflammatory diseases mediated by prostaglandin D 2 (PGD2) or other agonists acting at the CRTH2 receptor on cells including eosinophils, basophils and Th2 lymphocytes.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease
    International Journal of Molecular Sciences Review Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease Michiel Van Bulck 1,2 , Ana Sierra-Magro 1,2, Jesus Alarcon-Gil 1, Ana Perez-Castillo 1,2 and Jose A. Morales-Garcia 1,2,3,* 1 Instituto de Investigaciones Biomédicas (CSIC-UAM), Arturo Duperier, 4. 28029 Madrid, Spain; [email protected] (M.V.B.); [email protected] (A.S.-M.); [email protected] (J.A.-G.); [email protected] (A.P.-C.) 2 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Valderrebollo, 5, 28031 Madrid, Spain 3 Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain * Correspondence: [email protected] Received: 31 December 2018; Accepted: 3 February 2019; Published: 8 February 2019 Abstract: Neurodegenerative disorders affect around one billion people worldwide. They can arise from a combination of genomic, epigenomic, metabolic, and environmental factors. Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer’s and Parkinson’s diseases. A progressive neurodegenerative process and neuroinflammation occur, and no current therapies can prevent, slow, or halt disease progression. To date, no novel disease-modifying therapies have been shown to provide significant benefit for patients who suffer from these devastating disorders. Therefore, early diagnosis and the discovery of new targets and novel therapies are of upmost importance. Neurodegenerative diseases, like in other age-related disorders, the progression of pathology begins many years before the onset of symptoms. Many efforts in this field have led to the conclusion that exits some similar events among these diseases that can explain why the aging brain is so vulnerable to suffer neurodegenerative diseases.
    [Show full text]
  • Aryloxime Aryloximes Aryloxymes
    (19) TZZ___¥_T (11) EP 1 511 737 B1 (12) EUROPÄISCHE PATENTSCHRIFT (45) Veröffentlichungstag und Bekanntmachung des (51) Int Cl.: Hinweises auf die Patenterteilung: C07D 237/04 (2006.01) C07D 401/12 (2006.01) 17.02.2010 Patentblatt 2010/07 A61K 31/50 (2006.01) A61P 37/00 (2006.01) (21) Anmeldenummer: 03732395.3 (86) Internationale Anmeldenummer: PCT/EP2003/005173 (22) Anmeldetag: 16.05.2003 (87) Internationale Veröffentlichungsnummer: WO 2003/104205 (18.12.2003 Gazette 2003/51) (54) ARYLOXIME ARYLOXIMES ARYLOXYMES (84) Benannte Vertragsstaaten: • BEIER, Norbert AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 64354 Reinheim (DE) HU IE IT LI LU MC NL PT RO SE SI SK TR • SCHELLING, Pierre Benannte Erstreckungsstaaten: 64367 Mühltal (DE) LT LV • WOLF, Michael 64297 Darmstadt (DE) (30) Priorität: 10.06.2002 DE 10225574 (56) Entgegenhaltungen: (43) Veröffentlichungstag der Anmeldung: WO-A-98/06704 WO-A-99/65880 09.03.2005 Patentblatt 2005/10 Bemerkungen: (73) Patentinhaber: Merck Patent GmbH Die Akte enthält technische Angaben, die nach dem 64293 Darmstadt (DE) Eingang der Anmeldung eingereicht wurden und die nicht in dieser Patentschrift enthalten sind. (72) Erfinder: • EGGENWEILER, Hans-Michael 64291 Darmstadt (DE) Anmerkung: Innerhalb von neun Monaten nach Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents im Europäischen Patentblatt kann jedermann nach Maßgabe der Ausführungsordnung beim Europäischen Patentamt gegen dieses Patent Einspruch einlegen. Der Einspruch gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]